Phase II Trial of Carboplatin, Paclitaxel, Cetuximab and Bevacizumab Followed by Cetuximab and Bevacizumab in Advanced Non-Squamous Non-Small Cell Lung Cancer: SWOG S0536

INTRODUCTION: Cetuximab and bevacizumab have each been demonstrated to prolong survival when added to chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). However, the potential benefit of combining cetuximab and bevacizumab together with a platinum-based doublet had not been e...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Kim, Edward S., Moon, James, Herbst, Roy S., Redman, Mary W., Dakhil, Shaker R., Velasco, Mario R., Hirsch, Fred R., Mack, Philip C., Kelly, Karen, Heymach, John V., Gandara, David R.
Formato: Artigo
Idioma:Inglês
Publicado: 2013
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4072123/
https://ncbi.nlm.nih.gov/pubmed/24189513
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/JTO.0000000000000009
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares